Tag
Zealand Pharma A/S
2 articles
Zealand Pharma Shares Plunge 26% Over Obesity Drug Side Effects
Zealand Pharma A/S shares fell over 26% after Phase III trial of obesity drug survodutide revealed high discontinuation due to GI side effects.
In the 76‑week SYNCHRONIZE‑1 trial, survodutide achieved
Zealand Pharma Shares Down 26% After Trial
Zealand Pharma A/S shares fell over 26% after Phase III trial data showed high discontinuation due to gastrointestinal side effects.
The SYNCHRONIZE‑1 trial (725 patients, 76 weeks) reported up to 16.